Acumapimod (BCT197)

Acute exacerbations of chronic obstructive pulmonary disease. An oral p38 MAP kinase inhibitor that has completed Phase 2 development as first-line therapy for severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Acumapimod is given during a severe exacerbation to reduce the risk of further exacerbations. STATUS: Open-to-Partnership